A statement released today by Stifel about Vernalis PLC (LON:VER) holds the target price at 99.00GBX
- Updated: October 1, 2016
Stating a potential upside of 1.44%, Stifel hold steady the price target of Vernalis PLC (LON:VER) at 99.00GBX
On 09/22/2016, Panmure Gordon released a statement for Vernalis PLC (LON:VER) maintained the target price at 76.00GBX. At the time, this indicated a possible upside of 0.71%.
Boasting a price of 40.50GBX, Vernalis PLC (LON:VER) traded 3.70% higher on the day. With the last close down -8.10% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. The company has recorded a 50-day moving average of 43.63GBX and a two hundred day average of 45.70GBX. Volume of trade was down over the average, with 256,354 shares of VER changing hands under the typical 257,856
Vernalis PLC has one year low of 31.00GBX and a one year high of 79.00GBX and has a total market value of 0 GBX.
In addition to Stifel reporting its target price, a total of 5 analysts have released a research note on the company. The average stock price target is 83.60GBX with 2 firms rating the stock a strong buy, 2 firms rating the stock a buy, one analyst rating the company a hold, zero equity analysts rating the company a underperform, and finally 0 firms rating the stock a sell.
General Information About Vernalis PLC (LON:VER)
Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine. The Company also has four prescription cough cold products under development, and a pipeline of research and new chemical entity (NCE) development programs. Its commercial pipeline candidates include CCP-05, CCP-06, CCP-07 and CCP-08. The Company operates in the United Kingdom, Rest of Europe, North America and Rest of the World. The Company is also engaged in fragment- and structure-based drug discovery. It has two development products in the central nervous system (CNS) therapeutic area: the fatty acid amide hydrolase (FAAH) inhibitor V158866 for pain, and V81444, an adenosine A2A receptor antagonist as a treatment for CNS diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.